BIOMAT Database Logo BIOMAT Database Logo

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. 1998

H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Departments of Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA. hing.l.sham@abbott.com

The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease and ritonavir, the potent protease inhibitor ABT-378, which has a diminished interaction with Val 82, was designed. ABT-378 potently inhibited wild-type and mutant HIV protease (Ki = 1.3 to 3.6 pM), blocked the replication of laboratory and clinical strains of HIV type 1 (50% effective concentration [EC50], 0.006 to 0.017 microM), and maintained high potency against mutant HIV selected by ritonavir in vivo (EC50, </=0. 06 microM). The metabolism of ABT-378 was strongly inhibited by ritonavir in vitro. Consequently, following concomitant oral administration of ABT-378 and ritonavir, the concentrations of ABT-378 in rat, dog, and monkey plasma exceeded the in vitro antiviral EC50 in the presence of human serum by >50-fold after 8 h. In healthy human volunteers, coadministration of a single 400-mg dose of ABT-378 with 50 mg of ritonavir enhanced the area under the concentration curve of ABT-378 in plasma by 77-fold over that observed after dosing with ABT-378 alone, and mean concentrations of ABT-378 exceeded the EC50 for >24 h. These results demonstrate the potential utility of ABT-378 as a therapeutic intervention against AIDS.

UI MeSH Term Description Entries
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008297 Male Males
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
ABT-378: a second generation protease inhibitor.
October 1998, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
ABT-378: Abbott "second generation" protease inhibitor.
February 1997, AIDS treatment news,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
March 1995, Proceedings of the National Academy of Sciences of the United States of America,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
March 2001, AIDS (London, England),
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
May 1997, Antimicrobial agents and chemotherapy,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
October 1996, Drug metabolism and disposition: the biological fate of chemicals,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
August 2000, Antimicrobial agents and chemotherapy,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
March 1996, Drug metabolism and disposition: the biological fate of chemicals,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Naturally occurring protease inhibitors potent against the human immunodeficiency virus.
October 1996, Biochemical and biophysical research communications,
H L Sham, and D J Kempf, and A Molla, and K C Marsh, and G N Kumar, and C M Chen, and W Kati, and K Stewart, and R Lal, and A Hsu, and D Betebenner, and M Korneyeva, and S Vasavanonda, and E McDonald, and A Saldivar, and N Wideburg, and X Chen, and P Niu, and C Park, and V Jayanti, and B Grabowski, and G R Granneman, and E Sun, and A J Japour, and J M Leonard, and J J Plattner, and D W Norbeck
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
February 1995, Journal of virology,
Copied contents to your clipboard!